1019504-64-3

Upstream product

• 5680-79-5 glycine ethyl ester hydrochloride 
• 1122-91-4 4-bromo-benzaldehyde 
• 67-56-1 methanol 
• 623-33-6 glycine ethyl ester hydrochloride 
• 589-15-1 1-bromomethyl-4-bromobenzene 

Downstream Products

• 1613147-86-6 2-(N-(4-bromobenzyl)-2-nitrophenylsulfonamido)acetic acid 
• 1613147-87-7 6-bromo-2-(2-nitrophenylsulfonamido)-2,3-dihydroisoquinolin-4(1H)-one 
• 1613147-88-8 6-bromo-2-(2-nitrophenylsulfonyl)-1,2,3,4-tetrahydroisoquinolin-4-ol 
• 1613147-89-9 6-bromo-4-fluoro-2-(2-nitrophenylsulfonyl)-1,2,3,4-tetrahydroisoquinoline 
• 1613147-85-5 methyl 2-(N-(4-bromobenzyl)-2-nitrophenylsulfonamido)acetate 
• 1228660-48-7 1-(4-bromobenzyl)-3-isopropylimidazolidine-2, 4-dione 

Relevant academic research and scientific papers

Identification of a novel class of autotaxin inhibitors through cross-screening

Three novel series were generated in order to mimic the pharmacophoric features displayed by lead compound AM095, a lysophosphatidic acid (LPA1) receptor antagonist. Biological evaluation of this array of putative LPA1 antagonists le

SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted alkynyl compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE

The invention relates to A 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione derivative having the general Formula I wherein R1 is H, (C1-6)alkyl (optionally substituted with oxo, OR4, COOR5, halogen or CN), (C2-6)alkenyl, (C2-6)alkynyl, (C3-6)cycloalkyl or (C3-6)cycloalkyl(C1-3)alkyl; R2 and R2′ are independently H or (C1-3)alkyl; or R2 and R2′ form together with the carbon atom to which they are bound a (C3-5)cycloalkyl group; R3 represents H or 1 to 4 F substituents; Y represents or NR8R9; X represents CHR6, CF2, O, S, SO or SO2; R4 and R5 are (C1-6)alkyl; R6 is H, OR7 or CN; R7 is (C1-3)alkyl; R8 is (C5-7)cycloalkyl comprising a heteroatom selected from O, S, SO and SO2; R9 is H or (C1-4)alkyl; o and m represent the ortho or meta position of the substituent Y—CH2; or a pharmaceutically acceptable salt thereof; as well as to the use of said 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione derivatives in the treatment of pain such as for example peri-operative pain, chronic pain, neuropathic pain, cancer pain and pain and spasticity associated with multiple sclerosis.